| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.9 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.9 |